FY2024 EPS Estimates for BrainsWay Lifted by HC Wainwright

BrainsWay Ltd. (NASDAQ:BWAY - Free Report) - Analysts at HC Wainwright boosted their FY2024 earnings per share estimates for shares of BrainsWay in a research note issued on Monday, December 23rd. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $0.14 per share for the year, up from their prior estimate of $0.06. HC Wainwright currently has a "Buy" rating and a $16.00 target price on the stock. The consensus estimate for BrainsWay's current full-year earnings is $0.06 per share. HC Wainwright also issued estimates for BrainsWay's Q4 2024 earnings at $0.06 EPS, Q1 2025 earnings at $0.06 EPS, Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.08 EPS, Q4 2025 earnings at $0.10 EPS and FY2025 earnings at $0.32 EPS.

BrainsWay (NASDAQ:BWAY - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.03. BrainsWay had a net margin of 3.88% and a return on equity of 3.52%. The company had revenue of $10.50 million during the quarter, compared to the consensus estimate of $10.07 million. During the same period in the prior year, the business earned ($0.01) earnings per share.

Separately, Northland Securities lifted their target price on BrainsWay from $11.00 to $12.50 and gave the stock an "outperform" rating in a report on Thursday, October 3rd.

BrainsWay Trading Up 2.2 %

BWAY traded up $0.20 during trading on Wednesday, reaching $9.35. 39,528 shares of the company's stock were exchanged, compared to its average volume of 92,557. The stock has a market capitalization of $175.90 million, a PE ratio of 93.51 and a beta of 1.23. The firm has a fifty day moving average price of $9.84 and a two-hundred day moving average price of $8.26. BrainsWay has a one year low of $4.61 and a one year high of $10.98.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Acadian Asset Management LLC increased its position in shares of BrainsWay by 48.1% during the second quarter. Acadian Asset Management LLC now owns 259,787 shares of the company's stock worth $1,567,000 after acquiring an additional 84,371 shares in the last quarter. Good Life Advisors LLC raised its position in BrainsWay by 65.5% in the third quarter. Good Life Advisors LLC now owns 55,800 shares of the company's stock worth $516,000 after acquiring an additional 22,080 shares during the period. Perritt Capital Management Inc bought a new position in BrainsWay during the second quarter valued at $121,000. Finally, Rhumbline Advisers increased its holdings in BrainsWay by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 18,077 shares of the company's stock worth $110,000 after acquiring an additional 1,695 shares during the last quarter. 30.11% of the stock is owned by institutional investors.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.